Vyome Holdings, Inc. (NASDAQ:HIND) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Vyome Holdings, Inc. (NASDAQ:HIND) have earned an average rating of “Moderate Buy” from the six ratings firms that are currently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $9.25.

HIND has been the subject of several recent research reports. Chardan Capital began coverage on Vyome in a research report on Thursday, September 3rd. They issued a “buy” rating and a $3.50 price target for the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Vyome in a report on Wednesday, July 29th.

Institutional Investors Weigh In On Vyome

An institutional investor recently bought a new stake in Vyome stock. Millennium Management LLC purchased a new stake in shares of Vyome Holdings, Inc. (NASDAQ:HIND) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 45,144 shares of the company’s stock, valued at approximately $155,000. Millennium Management LLC owned about 0.80% of Vyome at the end of the most recent quarter. Institutional investors and hedge funds own 22.06% of the company’s stock.

Vyome Stock Down 1.4%

HIND stock opened at $2.06 on Thursday. Vyome has a 52 week low of $1.75 and a 52 week high of $9.56. The firm has a market capitalization of $14.46 million, a P/E ratio of -0.61 and a beta of 1.50. The company has a fifty day simple moving average of $2.18 and a two-hundred day simple moving average of $2.26.

Vyome (NASDAQ:HIND) last posted its earnings results on Wednesday, August 12th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $0.27 million during the quarter. Vyome had a negative return on equity of 197.33% and a negative net margin of 3,024.84%.

About Vyome

ReShape Lifesciences Inc, a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company’s product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract.